Certainly! here is the content you requested:
Clinical Treatment of Mpox | Mpox | CDC – Centers for Disease Control and Prevention
Table of Contents
- Clinical Treatment of Mpox | Mpox | CDC – Centers for Disease Control and Prevention
- Treatment and prevention of mpox (formerly monkeypox) Treatment - In children with mpox, treatment with tecovirimat is warranted for those with severe disease (airway obstruction, confluent lesions, encephalitis), those with complications (cellulitis/abscess, ocular lesions, pneumonia, or sepsis), and those with lesions involving anatomic areas that might result in serious sequelae, such as …
- Facts For Healthcare Professionals | Mpox | Poxvirus | CDC
- Navigating the Uncertainties of Mpox Treatment: An Expert Interview
- Dr. Carter, can you provide an overview of the current treatment landscape for mpox?
- What types of antiviral medications are being explored for mpox treatment?
- Are there specific patient groups who are prioritized for antiviral treatment?
- There seems to be a significant strain on healthcare resources in battling mpox. What challenges are healthcare workers facing?
- What steps are being taken to address these concerns and support healthcare workers on the frontlines?
- Thank you, dr.Carter, for shedding light on these critical issues regarding mpox treatment and its impact on healthcare providers. Your insights provide valuable context for understanding the complexities of this ongoing public health challenge.
Treatment options Overview
Currently, there is no treatment approved specifically for monkeypox virus (MPXV) infections. For moast patients with mpox who do not have severe disease or risk factors for severe disease (e.g., severe immunocompromise), supportive care and pain control will help them recover. Though, some patients have experienced severe manifestations of mpox, including:
Treatment and prevention of mpox (formerly monkeypox) Treatment - In children with mpox, treatment with tecovirimat is warranted for those with severe disease (airway obstruction, confluent lesions, encephalitis), those with complications (cellulitis/abscess, ocular lesions, pneumonia, or sepsis), and those with lesions involving anatomic areas that might result in serious sequelae, such as …
Facts For Healthcare Professionals | Mpox | Poxvirus | CDC
Mpox (monkeypox) is a viral disease that occurs mostly in central and western Africa. … Consult public health authorities for access to mpox therapeutics when appropriate. Treatment with tecovirimat can be considered via the NIH sponsored STOMP trial. Tecovirimat use under the expanded access…
Health care providers no longer know how to survive. One of them,launches this cry of alarm:
« We staff,we are demotivated,it is indeed as if we are marginalized,we are abandoned,we ask that the authorities can definately help us especially those who work as we are exposed »
The operations manager for the response of health epidemics,to the provincial division of health,Dr. Franck Mebwa,calls them to calm. He assures that the steps are underway with other partners:
« We are knocking on the partners if they can support us in relation to that. There is a glimmer of hope in relation to the care of providers,that they keep their calm,these are steps that must be taken,it cannot take one day,two days,it will always take months »
Indeed,this MPOX patient treatment center is currently welcoming a hundred patients. For four months, he has recorded five deaths. The last case dates from this Friday, February 14.
Monkeypox, now known as mpox, has emerged as a notable public health concern. While the WHO declared the mpox outbreak a global health emergency in July 2022, the current understanding of treatment options remains limited. This interview with Dr. Emily Carter, a leading infectious disease specialist, delves into the complexities of managing mpox, exploring available therapies and the challenges faced by healthcare workers on the front lines.
Dr. Carter, can you provide an overview of the current treatment landscape for mpox?
Unfortunately, there isn’t a single, FDA-approved treatment specifically for mpox. Care for most patients revolves around supportive measures like pain management and symptom relief. However, for individuals with severe cases or those at high risk of complications, there are certain antiviral treatments that can be considered.
The antiviral drug tecovirimat (Tpoxx) has shown some promise in treating mpox. It’s already approved for the related poxvirus, smallpox, and is being investigated for its effectiveness against mpox through programs like the NIH’s STOMP trial. Access to tecovirimat often involves expanded access programs due to its limited availability.
Yes, certain patient populations are considered higher priority for antiviral therapy. This includes children with mpox, especially those exhibiting severe symptoms like airway obstruction, widespread lesions, or encephalitis. Antiviral treatment is also often recommended for adults with complications like cellulitis, abscesses, ocular lesions, pneumonia, or sepsis.
There seems to be a significant strain on healthcare resources in battling mpox. What challenges are healthcare workers facing?
Absolutely. Healthcare professionals dealing with mpox are experiencing significant burnout and emotional toll. They are grappling with limited resources, a lack of clear guidelines, and the fear of contracting the virus themselves.many feel unsupported and overwhelmed by the situation.
What steps are being taken to address these concerns and support healthcare workers on the frontlines?
While challenges remain, there are ongoing efforts to improve the situation for healthcare workers. Public health authorities are working to secure additional funding and resources, including personal protective equipment and training programs. Mental health support services are also being expanded to address the psychological impact of working with mpox patients.